New Treatment for Benign Prostatic Enlargement
DH CIRCULAR No. 67/2020
DH 899/2020 30th September 2020
Attention All: Consultants
Re: New Treatment for Benign Prostatic Enlargement
Following the inclusion of Benign Prostatic Enlargement (BPE) to the Fifth Schedule of the Social Security Act, it is being brought to your attention that further new treatment for BPE is now available on the Government Formulary List (GFL).
Alfuzosin 10mg prolonged release tablets (an alpha-1 adrenoreceptor antagonist) and Dutasteride 0.5mg tablets (a 5-alpha reductase inhibitor) can now be prescribed by Consultant Urologists
In order to decrease unnecessary hardship on the patients, those who require Alfuzosin or Dutasteride can also visit their Consultant, Resident Specialist, Primary Care Physician or GP to fill in the attached application form. These completed forms can either be taken by hand to Customer Care at MDH or forwarded as soft copy to email@example.com for vetting by a Consultant Urologist. A Schedule V card will then be issued and sent to the patient by post once application is approved.
Other treatment previously made available on the GFL for BPE is Doxazocin 2mg tablets and Finasteride 5mg tablets.
For your attention please.
Dr Denis Vella Baldacchino
Chief Medical Officer
Schedule V Form for BPE treatment